Ghrelin's second life: From appetite stimulator to glucose regulator

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 25

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

384

HTML

2175

Tables (1-2)

270

Sum=2829

Jul 7, 2012 (publication date) through Aug 28, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jul 7, 2012; 18(25): 3183-3195
Published online Jul 7, 2012. doi: 10.3748/wjg.v18.i25.3183

Table 2 Ghrelin antagonists under development for the treatment of obesity and type 2 diabetes

Ghrelin antagonists
Drug	Company	Target	Status
TZP-301	Tranzyme Pharma	Obesity, metabolic syndrome	Lead optimization
Two families of ghrelin antagonists	Helsinn Pharmaceuticals	Obesity, metabolic syndrome	Lead optimization
AEZS-123	Aeterna Zenartis	Obesity, alcohol abuse	Preclinical
Ghrelin antagonist	Novartis (Elixir)	Type 2 diabetes, obesity	Preclinical

Citation: Verhulst PJ, Depoortere I. Ghrelin's second life: From appetite stimulator to glucose regulator. World J Gastroenterol 2012; 18(25): 3183-3195
URL: https://www.wjgnet.com/1007-9327/full/v18/i25/3183.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i25.3183